Conference Calendar - The 33rd International Papillomavirus Conference

Times are stated in CEST (GMT + 2 / UTC + 2)
Every effort has been made to convert the IPVC 2020 scientific program into a fully virtual program. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive program on the virtual conference platform. Please note that some presenters were not able to pre-record their presentations, therefore there are still some sessions with missing presentations.

To view the pre-conference workshops, you need to register for them separately. Please contact: reg_ipvc20@kenes.com
You will then receive an email with instructions on how to login to the workshops’ platform.

Displaying One Session

View

Public Health Oral Session

00990 - Oral Session 15: VACCINATION V. Impact and effectiveness (ID 54)

Session Type

Public Health Oral Session

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER \u003Csmall\u003E(ID 412)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":412,"presentation":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER \u003Csmall\u003E(ID 412)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"P\u00e4r Spar\u00e9n (Sweden)","photo":""},"playlist":[{"name":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/1269F6D7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.vtt"}]},{"name":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN \u003Csmall\u003E(ID 1078)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1078,"presentation":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN \u003Csmall\u003E(ID 1078)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Mona Saraiya (United States of America)","photo":""},"playlist":[{"name":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/6899418.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.vtt"}]},{"name":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA AFTER 10 YEARS OF THE HPV VACCINATION PROGRAM \u003Csmall\u003E(ID 660)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":660,"presentation":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA AFTER 10 YEARS OF THE HPV VACCINATION PROGRAM \u003Csmall\u003E(ID 660)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Laurie Smith (Canada)","photo":""},"playlist":[{"name":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/963A7278.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.vtt"}]},{"name":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE CERVICAL PRECANCER INCIDENCE RATES, UNITED STATES, 2008-2015 \u003Csmall\u003E(ID 175)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":175,"presentation":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE CERVICAL PRECANCER INCIDENCE RATES, UNITED STATES, 2008-2015 \u003Csmall\u003E(ID 175)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Julia W. Gargano (United States of America)","photo":""},"playlist":[{"name":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/D457A73F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.vtt"}]}]

Oral Session 15: VACCINATION V. Impact and effectiveness Hall D

EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER (ID 412)

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 15: VACCINATION V. Impact and effectiveness

Lecture Time

09:00 - 09:12

Presenter

Pär Sparén (Sweden)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 15: VACCINATION V. Impact and effectiveness Hall D

IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN (ID 1078)

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 15: VACCINATION V. Impact and effectiveness

Lecture Time

09:12 - 09:24

Presenter

Mona Saraiya (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 15: VACCINATION V. Impact and effectiveness Hall D

POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA AFTER 10 YEARS OF THE HPV VACCINATION PROGRAM (ID 660)

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 15: VACCINATION V. Impact and effectiveness

Lecture Time

09:24 - 09:36

Presenter

Laurie Smith (Canada)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 15: VACCINATION V. Impact and effectiveness Hall D

VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE CERVICAL PRECANCER INCIDENCE RATES, UNITED STATES, 2008-2015 (ID 175)

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 15: VACCINATION V. Impact and effectiveness

Lecture Time

09:36 - 09:48

Presenter

Julia W. Gargano (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 15: VACCINATION V. Impact and effectiveness Hall D

Online Chat Q&A for this session is called: PUBLIC HEALTH ORAL SESSION 15: VACCINATION V. IMPACT AND EFFECTIVENESS. You can join the online chat Q&A and discussions for this session by going back to the Lobby and entering the Networking Lounge. Speakers are encouraged to be online in the chat room at the time this session is stated to end. All times are in CEST. (ID 1813)

Session Date

07/24/2020

Session Time

09:00 - 10:00

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 15: VACCINATION V. Impact and effectiveness

Lecture Time

09:48 - 09:48